a State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, School of Life Science , Xiamen University , Xiamen , Fujian , China.
b Key Laboratory for Cancer T-Cell Theranostics and Clinical Translation (CTCTCT), Translational Medicine Research Center, School of Pharmaceutical Science , Xiamen University , Xiamen , Fujian , China.
Hum Vaccin Immunother. 2018 Feb 1;14(2):292-303. doi: 10.1080/21645515.2017.1391433. Epub 2017 Dec 1.
Human cytomegalovirus (HCMV) causes considerable morbidity and disability in high risk, immunocompromised populations including recipients of solid organ transplants, and fetuses whose immune systems are not yet mature. Vaccines aimed at ameliorating the severity of disease and preventing HCMV infection can be categorized into two main approaches of vaccine design, with one focusing on virus modification and the other on individual antigens. However, no candidates in either class have been successful in achieving durable and protective immunity. Recent studies on the natural immune response provide new insight into HCMV vaccine strategy. In particular, studies have demonstrated that the incorporation of a pentameric complex is necessary for a vaccine to generate the potent neutralizing antibodies often seen in seropositive individuals. This review summarizes recent findings in the development of HCMV vaccines and key considerations that should be taken into vaccine design based on improved understanding of natural HCMV immunity.
人巨细胞病毒（HCMV）可导致高危、免疫功能低下人群（包括实体器官移植受者和免疫系统尚未成熟的胎儿）出现严重疾病和残疾。旨在减轻疾病严重程度和预防 HCMV 感染的疫苗可分为两种主要的疫苗设计方法，一种方法侧重于病毒修饰，另一种方法侧重于个体抗原。然而，两类候选疫苗都未能成功获得持久和保护性免疫。近期对天然免疫反应的研究为 HCMV 疫苗策略提供了新的见解。特别是，研究表明，五聚体复合物的掺入对于疫苗产生经常在血清阳性个体中看到的强效中和抗体是必要的。本综述总结了 HCMV 疫苗开发的最新发现，并基于对天然 HCMV 免疫的理解，提出了疫苗设计中应考虑的关键问题。
